TG earnings missed by $0.02, revenue topped estimates
TG (TGTX) reported Q3 EPS of $0.35, missing estimates by $0.02, but revenue of $259.94M exceeded expectations. The company guided FY 2026 revenue to $915M-$920M, below consensus. TGTX stock is up 24.80% in 3 months and 97.46% in 12 months.
How this was made
The 30-second read
Why it matters
The earnings miss and lower guidance are likely to trigger a sell‑off, especially given the stock's recent strong run‑up.
Market read
Primary earnings news for a micro‑cap; actionable for short‑term traders.
What to watch
Potential upcoming data releases or partnership announcements that could offset the guidance shortfall.
Background
TG is a small‑cap biotech listed on NASDAQ. The article is a standard earnings recap with no additional commentary.
Ticker impact
TG reported Q3 EPS of $0.35, missing estimates by $0.02 and gave FY2026 revenue guidance of $915M-$920M, below the consensus of $960.30M.
likely pressure as the market prices in the revenue guidance shortfall
The miss and below‑consensus guidance are fresh, material facts that typically trigger a sell‑off in small‑cap stocks.
Market effects
The miss may weigh on the broader biotech/clinical‑stage sector, especially other small‑cap companies with similar guidance expectations.
Limited to U.S. markets; no broader regional effect noted.
Minimal global impact beyond investors tracking micro‑cap earnings.
Counterpoint
If the market has over‑reacted to the guidance miss, a short‑term bounce could occur on any positive catalyst.
Key entities
- companyTG
Biotech firm reporting Q3 results.
